ART6043
gBRCA-mutated HER2-negative breast cancer (and other solid tumors)
Phase 1/2Active
Key Facts
Indication
gBRCA-mutated HER2-negative breast cancer (and other solid tumors)
Phase
Phase 1/2
Status
Active
Company
About Artios Pharma
Artios Pharma is a clinical-stage biotech positioned as a leader in the DNA Damage Response (DDR) field, building on the legacy of its founders who invented the blockbuster PARP inhibitor olaparib. The company is advancing a pipeline with first-in-class potential, including alnodesertib (ATR inhibitor) and ART6043 (Polθ inhibitor), supported by its proprietary DcoDeR discovery platform. With a seasoned leadership team and a strategy targeting high-unmet-need cancers, Artios aims to deliver transformative treatments through both monotherapy and combination regimens.
View full company profile